CytoMed Therapeutics Limited has submitted a cash bid to acquire selected assets of TC BioPharm Limited, following the appointment of joint administrators to TC BioPharm earlier this month. Both companies focus on developing donor-derived allogeneic gamma delta T cell therapies for cancer treatment. CytoMed recently completed an acquisition of a licensed cord blood bank in Malaysia and aims to leverage these assets to accelerate its development of affordable cell-based immunotherapies for cancer and autoimmune diseases. The company believes the addition of TC BioPharm's assets will strengthen its expertise in allogeneic cell therapies and support its mission to provide new therapeutic options for patients with unmet medical needs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544979-en) on October 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.